Dosing and Administration
TREMFYA® has a convenient dosing regimen, with 6 doses per year in PsA and Pso1
For PsA patients at high risk for joint damage according to clinical judgement, a dose of 100 mg every 4 weeks may be considered1
In PsA clinical studies, an increased incidence of liver enzyme elevations was observed in patients treated with TREMFYA® q4w compared to patients treated with TREMFYA® q8w or placebo. When prescribing TREMFYA® q4w in psoriatic arthritis, it is recommended to evaluate liver enzymes at baseline and thereafter according to routine patient management. If increases in ALT or AST are observed and drug-induced liver injury is suspected, TREMFYA® should be temporarily interrupted until this diagnosis is excluded1
TREMFYA® offers patients simple, flexible dosing1
"How to use" video Tremfya is suitable for patients and caregivers. It includes helpful information on preparing and self-administrating TREMFYA® injections
TREMFYA® provides self-administration via One-Press – a device highly accepted by patients2
98.4% of patients starting on TREMFYA® were satisfied or very satisfied with their self-injections with One-Press at Week 122
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via: HPRA Pharmacovigilance Website: www.hpra.ie. Adverse events should also be reported to Janssen Sciences Ireland UC on 1800 709 122 or at dsafety@its.jnj.com. |
References
- TREMFYA Summary of Product Characteristics, available at https://www.medicines.ie/medicines/tremfya-100-mg-solution-for-injection-in-pre-filled-pen-34706/spc#tabs
- Ferris L, et al. J Derm Treat 2020;31:152-159.
